Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethazan SCHEMBL49056 | 0.91 | PDE4A (0.73) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120975 | 0.88 | ADORA2B (0.88) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120979 | 0.88 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL683551 | 0.87 | ADORA2B (0.70) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120999 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120983 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120989 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16121000 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL16120982 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 | |
| SCHEMBL19969384 | 0.86 | ADORA2B (0.85) | ADORA2BLMNAMAPTRXFP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ADORA2B 786/4885LMNA 2155/4885MAPT 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.